Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy

被引：0
|
作者：
Knievel, Kerry [1 ]
Lombard, Louise [2 ]
Buchanan, Andrew [2 ]
Baygani, Simin [2 ]
Raskin, Joel [2 ]
Tobin, Joshua [3 ]
机构：
[1] Barrow Neurol Inst, Phoenix, AZ 85013 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] 21st Century Neurol, Xenosci, Phoenix, AZ 85013 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O30
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pharmacogenetics of migraine: impact of serotonin transporter polymorphisms and haplotypes on triptan response
    Viana, M.
    Balzaretti, G.
    Monaco, F.
    Mittino, D.
    Sances, G.
    Allena, M.
    Tassorelli, C.
    Nappi, G.
    Canonico, P. L.
    Genazzani, A. A.
    Terrazzino, S.
    CEPHALALGIA, 2011, 31 (01) : 116 - 116
  • [42] Characteristics of patients with inadequate responses to acute triptan treatment for menstrual migraine
    Tobin, J.
    Shaw, R.
    Pawsey, S.
    Campbell, J. C.
    Brandes, J. L.
    MacGregor, E. A.
    HEADACHE, 2007, 47 (05): : 786 - 786
  • [43] Lasmiditan (200 Mg and 100 Mg) Compared to Placebo for Acute Treatment of Migraine
    Kuca, B.
    Wietecha, L.
    Berg, P.
    Aurora, S. K.
    HEADACHE, 2017, 57 (08): : 1311 - 1312
  • [44] Phase 3 Study (SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Case, Michael G.
    Selzler, Katherine J.
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 367 - 368
  • [45] Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis
    Maiti, Rituparna
    Mishra, Archana
    Puliappadamb, Haridas Mundot
    Jena, Monalisa
    Srinivasan, Anand
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (12): : 1534 - 1544
  • [46] Lasmiditan (200 mg and 100 mg) compared to placebo for acute treatment of migraine
    Kuca, Bernice
    Wietecha, Linda
    Berg, Paul H.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [47] PHASE 3 STUDY (SPARTAN) OF LASMIDITAN COMPARED TO PLACEBO FOR ACUTE TREATMENT OF MIGRAINE
    Wietecha, L. A.
    Kuca, B.
    Case, M. G.
    Selzler, K. J.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 57 - 58
  • [48] Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study
    Viana, Michele
    Sances, Grazia
    Terrazzino, Salvatore
    Zecca, Chiara
    Goadsby, Peter J.
    Tassorelli, Cristina
    CEPHALALGIA, 2021, 41 (02) : 197 - 202
  • [49] Consistency of response of remote electrical neuromodulation for the acute treatment of migraine
    Levin, Morris
    Lin, Tamar
    Harris, Dagan
    Ironi, Alon
    Jashek, Ronen
    CEPHALALGIA, 2019, 39 : 198 - 198
  • [50] Predicting treatment-response to prescription acute migraine medications
    Ezzati, A.
    Buse, D. C.
    Reed, M. L.
    Pavlovic, J. M.
    Armand, C. E.
    Fanning, K. M.
    Martin, V. T.
    Lipton, R. B.
    HEADACHE, 2021, 61 : 48 - 48
12345